Q2 2024 EPS Estimates for Repligen Co. Cut by William Blair (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Stock analysts at William Blair lowered their Q2 2024 earnings per share (EPS) estimates for Repligen in a research note issued to investors on Thursday, May 2nd. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings per share of $0.29 for the quarter, down from their prior estimate of $0.32. The consensus estimate for Repligen’s current full-year earnings is $1.46 per share. William Blair also issued estimates for Repligen’s Q1 2025 earnings at $0.49 EPS, Q2 2025 earnings at $0.53 EPS, Q3 2025 earnings at $0.59 EPS and Q4 2025 earnings at $0.62 EPS.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The business had revenue of $151.31 million for the quarter, compared to the consensus estimate of $150.06 million. Repligen had a return on equity of 3.94% and a net margin of 2.44%. The business’s revenue was down 17.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.64 earnings per share.

Other analysts have also issued reports about the company. JPMorgan Chase & Co. dropped their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday. Stifel Nicolaus boosted their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, KeyCorp boosted their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $197.75.

Repligen Stock Performance

Shares of Repligen stock opened at $167.05 on Friday. The business’s fifty day simple moving average is $180.81 and its 200 day simple moving average is $173.90. The firm has a market capitalization of $9.33 billion, a P/E ratio of 668.23, a price-to-earnings-growth ratio of 5.19 and a beta of 1.03. Repligen has a 12 month low of $110.45 and a 12 month high of $211.13. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.

Insider Activity

In other news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now directly owns 14,135 shares in the company, valued at $2,799,860.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Karen A. Dawes sold 1,000 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now directly owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO James Bylund sold 4,373 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 25,597 shares of company stock worth $5,039,532. 1.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Repligen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RGEN. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in Repligen by 130.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 11,500 shares of the biotechnology company’s stock worth $1,829,000 after buying an additional 6,500 shares in the last quarter. Raymond James & Associates boosted its holdings in shares of Repligen by 3.5% in the 3rd quarter. Raymond James & Associates now owns 67,219 shares of the biotechnology company’s stock worth $10,688,000 after purchasing an additional 2,283 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Repligen by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock worth $190,117,000 after purchasing an additional 137,220 shares in the last quarter. Forsta AP Fonden purchased a new position in shares of Repligen in the 3rd quarter worth about $1,908,000. Finally, Verdence Capital Advisors LLC boosted its holdings in shares of Repligen by 6.7% in the 3rd quarter. Verdence Capital Advisors LLC now owns 2,163 shares of the biotechnology company’s stock worth $344,000 after purchasing an additional 135 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.